Gonadorelin

Gonadorelin is a synthetic decapeptide identical to endogenous GnRH, the hypothalamic neuropeptide that drives the HPG axis. The peptide acts at GnRH receptors on the anterior pituitary, triggering LH and FSH release. LH stimulates testicular Leydig cells to produce testosterone in men. FSH supports spermatogenesis. The sequence is identical to native GnRH: pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. Gonadorelin was previously FDA-approved as Factrel (gonadorelin hydrochloride, diagnostic indication for HPG axis testing) and Lutrepulse (gonadorelin acetate, pulsatile delivery for hypothalamic amenorrhea). Both products have been withdrawn for commercial reasons. Compounded gonadorelin is the principal current source. Off-label use as a TRT adjunct to preserve testicular function is widespread despite the lack of FDA approval and a contested 503A compounding status. WADA prohibits gonadorelin under Section S2.

The HPG Axis and GnRH Biology

The hypothalamic-pituitary-gonadal axis is the central reproductive hormone signaling system in vertebrates:

1. Hypothalamus → releases GnRH in pulsatile fashion (a pulse every 60-120 minutes in adult men)
2. Anterior pituitary → GnRH binds pituitary GnRH receptors, triggers LH and FSH release
3. Testes (men) → LH stimulates Leydig cells to produce testosterone. FSH stimulates Sertoli cells to support spermatogenesis
4. Negative feedback → testosterone and inhibin feed back to hypothalamus and pituitary, regulating GnRH/LH/FSH pulse amplitude

The key pharmacological feature of this axis: pulsatile GnRH stimulation maintains pituitary responsiveness, while continuous GnRH stimulation paradoxically downregulates pituitary GnRH receptors and shuts down LH/FSH release. This is the basis for both natural fertility physiology and the use of GnRH agonists (leuprolide, goserelin) for chemical castration in prostate cancer.

The 1978 Belchetz paper in Science was a foundational demonstration of this pulsatile-vs-continuous principle in primate models.

Historical FDA Approvals

Factrel (gonadorelin hydrochloride, Wyeth) was FDA-approved for diagnostic use:

• Indication: testing the functionality of the HPG axis, particularly to distinguish hypothalamic from pituitary causes of hypogonadism
• Mechanism: single IV bolus of 100 mcg gonadorelin, with measurement of LH and FSH response over 60-90 minutes
• An LH/FSH response indicated functional pituitary GnRH receptors
• Absence of response suggested pituitary pathology (e.g., pituitary adenoma, Sheehan's syndrome)

Lutrepulse (gonadorelin acetate) was FDA-approved for therapeutic use:

• Indication: induction of ovulation in women with hypothalamic amenorrhea
• Delivery: pulsatile administration via portable pump, typically 5 mcg every 90 minutes intravenously or subcutaneously
• The pulsatile delivery mimicked natural hypothalamic GnRH pulse frequency
• Required for ovulation induction in women with intact pituitary but absent hypothalamic GnRH (e.g., Kallmann syndrome, functional hypothalamic amenorrhea)

Both products have been withdrawn from the US market. The withdrawals were for commercial reasons (low utilization, complexity of pulsatile pump systems, competition from alternative therapies like clomiphene and HCG) rather than safety or efficacy concerns.

Current Compounding Pharmacy Status

After the brand-name withdrawals, 503A compounding pharmacies have continued to produce gonadorelin under patient-specific prescriptions. The legal status of this compounding is contested:

• Under 21 U.S.C. § 353a(b)(1)(A)(i), a bulk drug substance that is a component of an FDA-approved drug qualifies for 503A compounding
• Whether gonadorelin's prior approvals (since withdrawn for commercial reasons) satisfy this criterion is an active interpretive question
• FDA has not formally resolved the question
• Pharmacy practice varies by state and by interpretation
• FDA has issued occasional enforcement actions against compounders selling gonadorelin

The result is that compounded gonadorelin is widely available through TRT clinics and men's health practices, but the regulatory foundation is uncertain and could change with FDA enforcement actions.

Off-Label TRT Adjunct Use

The dominant current use of gonadorelin is off-label as a TRT adjunct:

The clinical problem: exogenous testosterone shuts down the HPG axis through negative feedback. The hypothalamus stops releasing GnRH, the pituitary stops releasing LH and FSH, and the testes:

• Stop producing endogenous testosterone (testicular atrophy)
• Stop producing sperm (infertility)
• Shrink in volume (visible and palpable atrophy)

The proposed solution with gonadorelin: provide exogenous GnRH signaling to the pituitary, maintaining LH and FSH release, which maintains testicular function despite exogenous testosterone.

Clinical effectiveness questions:

• The very short half-life (2-4 minutes) means typical off-label dosing (a few injections per week) may not maintain physiological pituitary stimulation
• Continuous administration would downregulate pituitary receptors (counterproductive)
• True pulsatile delivery via pump (5 mcg every 90 minutes) would be ideal pharmacologically but impractical for outpatient TRT
• Individual response varies substantially
• No randomized controlled trials specifically test gonadorelin for TRT fertility/testicular preservation

The mismatch between gonadorelin's pharmacokinetics and the practical dosing schedules used in TRT clinics is a real pharmacological concern, though clinical experience suggests some benefit can be achieved.

Comparison to Alternatives

HCG (human chorionic gonadotropin):

• Mechanism: mimics LH, acts directly on testicular Leydig cells
• Half-life: 24-36 hours (much longer than gonadorelin)
• Advantages: longer half-life, more clinical research, established TRT adjunct
• Disadvantages: bypasses pituitary (less physiological), no FSH stimulation, more estrogen conversion, supply chain issues, more expensive

Enclomiphene (and Clomiphene):

• Mechanism: SERMs that block estrogen feedback at hypothalamus, increasing endogenous GnRH and LH/FSH
• Advantages: oral administration, increases endogenous gonadotropin signaling
• Disadvantages: not FDA-approved for TRT use, depends on functional HPG axis

Kisspeptin (Kisspeptin-10, Kisspeptin-54):

• Mechanism: acts upstream of GnRH at the hypothalamus, stimulating endogenous GnRH release
• Status: investigational, very limited 503A availability
• See separate Kisspeptin-10 and Kisspeptin-54 articles

Regulatory Status

• FDA: Not currently approved. Factrel and Lutrepulse withdrawn. 503A compounding under contested interpretation.
• EMA: Native GnRH (gonadorelin) is available in some European countries through specialty pharmacies for diagnostic and fertility uses
• WADA: Prohibited under Section S2 (Peptide Hormones, Growth Factors, Related Substances) at all times in all sports

Gonadorelin's mechanism is straightforward: it is identical to endogenous GnRH and acts on the same receptor (pituitary GnRH receptor, also called GnRHR or LHRHR).

GnRH Receptor Pharmacology

The GnRH receptor is a Gq-coupled G protein-coupled receptor (GPCR) expressed predominantly on gonadotrope cells of the anterior pituitary. Receptor activation triggers:

• Phospholipase C activation
• IP3 and DAG production
• Intracellular calcium release
• PKC activation
• Synthesis and release of LH and FSH from gonadotrope secretory granules

Pulsatile vs Continuous Signaling: The Pivotal Pharmacology

The most important pharmacological feature of GnRH signaling is the pulsatile vs continuous distinction:

• Pulsatile GnRH (60-120 minute intervals): maintains pituitary GnRH receptor expression and LH/FSH release. This is the natural physiological pattern.
• Continuous GnRH (sustained high concentrations): causes pituitary GnRH receptor downregulation and internalization, leading to suppression of LH and FSH release after an initial flare period of 1-2 weeks.

This biology underlies the clinical use of GnRH agonists for chemical castration in prostate cancer:

• Initial administration causes a "flare" of LH and testosterone (1-2 weeks)
• Continued administration causes receptor desensitization and sustained LH/testosterone suppression

For TRT adjunct use, the goal is pulsatile stimulation to maintain testicular function. Whether typical off-label gonadorelin dosing schedules (twice or thrice weekly subcutaneous injections of 100-400 mcg) achieve this is questionable.

Downstream HPG Axis Effects

After successful pituitary stimulation:

• LH acts on testicular Leydig cells via the LHCG receptor, increasing testosterone biosynthesis (cholesterol → pregnenolone → progesterone → androstenedione → testosterone)
• FSH acts on testicular Sertoli cells, supporting spermatogenesis and inhibin B production
• Together, these maintain testicular volume, intratesticular testosterone (required for spermatogenesis), and sperm production

In women (relevant for the historical Lutrepulse indication):

• LH triggers ovulation and supports corpus luteum function
• FSH supports follicular development

Pharmacokinetics

The pharmacokinetic profile is the principal practical limitation:

• Half-life: 2-4 minutes in plasma after IV administration, slightly longer after subcutaneous
• Bioavailability: subcutaneous bioavailability variable but adequate for pituitary stimulation if dosed correctly
• Metabolism: rapid proteolytic degradation, no specific active metabolites
• Excretion: renal

The very short half-life means that:

• Sustained continuous exposure is essentially impossible with peripheral administration
• Pulsatile delivery via pump is the only way to maintain physiological signaling pattern
• Typical TRT off-label dosing (a few subcutaneous injections per week) produces brief, intermittent pulses, which is closer to the physiological pattern than continuous infusion would be, but not equivalent to natural hypothalamic pulse frequency

Effects in FDA-approved historical indications:

• Factrel (diagnostic): reliable LH and FSH response within 60-90 minutes after 100 mcg IV bolus in subjects with functional HPG axis. Validated for distinguishing hypothalamic from pituitary causes of hypogonadism.
• Lutrepulse (ovulation induction): successful induction of ovulation in women with hypothalamic amenorrhea using pulsatile delivery via portable pump.

Effects in off-label TRT adjunct use (uncontrolled clinical observation):

• Preservation of testicular volume during exogenous testosterone administration (some patients)
• Maintained or improved sperm parameters in men on TRT (variable response)
• Some patients report maintained subjective testicular sensation and function
• Response highly variable from one patient to another
• Effectiveness depends on dosing protocol, individual pituitary responsiveness, and TRT regimen

Effects in post-cycle therapy (PCT) after anabolic steroid use (off-label):

• Stimulation of HPG axis recovery (variable success)
• Combined with SERMs (clomiphene, enclomiphene) in some PCT protocols
• No controlled trials specifically validating gonadorelin for PCT

Honest evidence framing: gonadorelin has well-established pharmacology in its historical FDA-approved indications (diagnostic HPG testing, ovulation induction). For the dominant current use (TRT fertility/testicular preservation), the evidence base is observational and uncontrolled. The pharmacokinetic mismatch between gonadorelin's 2-4 minute half-life and typical off-label dosing schedules raises real questions about whether the typical TRT-adjunct protocols achieve physiologically meaningful pituitary stimulation. Individual response varies substantially.

Important note: gonadorelin's off-label dosing has no FDA approval. The doses described below come from compounding pharmacy protocols and historical FDA-approved indications.

Historical FDA-approved doses:

• Factrel diagnostic: 100 mcg IV bolus, single dose
• Lutrepulse ovulation induction: 5 mcg every 90 minutes via pulsatile pump (IV or SC), continued through follicular phase

Off-label TRT adjunct protocols:

• Standard daily protocol: 100-200 mcg subcutaneously daily
• Twice-weekly protocol: 200-400 mcg subcutaneously 2-3 times per week
• Pulsatile attempt: multiple small doses (25-50 mcg) throughout the day to better mimic natural pulse pattern
• Cycle length: continuous use during TRT (months to years)

Off-label post-cycle therapy protocols:

• 100-200 mcg subcutaneously daily for 4-8 weeks after AAS cycle
• Often combined with SERM (clomiphene or enclomiphene)
• Sometimes combined with HCG in the initial phase

Routes:

• Subcutaneous: most common off-label route
• Intravenous: historical Factrel diagnostic use
• Pulsatile pump: historical Lutrepulse use, not common in current TRT contexts due to complexity
• Intramuscular: less common, similar pharmacokinetics to SC

Reconstitution and storage:

• Lyophilized peptide reconstituted with bacteriostatic water or sodium chloride
• Refrigeration after reconstitution
• Compounding pharmacy preparations typically come pre-reconstituted with stated stability
• Stability: typically 2-4 weeks at 2-8°C, varies by formulation

Pharmacokinetic considerations:

• Half-life of 2-4 minutes means single doses produce only transient pulses
• The mismatch between this short half-life and typical multi-day dosing schedules is real
• Pulsatile pump delivery (the original Lutrepulse approach) is pharmacologically superior but practically impractical for routine TRT

Special populations:

• Pregnancy: contraindicated (would interfere with HPG axis during pregnancy)
• Breastfeeding: avoid
• Pediatric: not appropriate outside specific endocrinology indications
• Hormone-sensitive cancers (prostate, breast): caution due to potential HPG axis stimulation
• Athletes subject to WADA testing: prohibited at all times
• Active pituitary pathology: caution

Adverse effects observed in FDA-approved historical use (Factrel, Lutrepulse):

• Headache (mild, transient)
• Nausea (uncommon)
• Mild abdominal discomfort
• Injection-site reactions (mild)
• Hot flashes (uncommon)
• Rare hypersensitivity reactions

Adverse effects in off-label TRT adjunct use (anecdotal):

• Mild injection-site reactions
• Headache (occasional)
• Mood changes (variable)
• Possible breakthrough estrogen elevation if testicular testosterone production is restored
• Variability in subjective testosterone effect

Theoretical concerns:

• Receptor downregulation from continuous administration: theoretically, frequent dosing could cause some degree of pituitary GnRH receptor desensitization, paradoxically reducing endogenous LH/FSH after initial flare. The clinical relevance at typical off-label doses is unclear.
• Tachyphylaxis: some patients report diminished response over time
• Hormone-sensitive cancer concerns: HPG axis stimulation could theoretically affect hormone-sensitive cancers (prostate, breast). Standard practice excludes use in these populations.
• Compounding pharmacy quality: lot-to-lot variability, potential for degradation products, identity verification varies by pharmacy
• Pituitary disorders: caution with active pituitary pathology

Pregnancy: contraindicated.

Breastfeeding: avoid.

Pediatric: not appropriate outside specific endocrinology indications (e.g., delayed puberty workup under specialist care).

Athletes: WADA-prohibited under Section S2. Use carries doping-violation risk.

Drug interactions:

• Dopamine agonists (cabergoline, bromocriptine): can affect pituitary responsiveness
• Other hormonal agents (testosterone, estrogen, progesterone): can affect HPG axis interpretation
• GnRH agonists (leuprolide, goserelin): avoid concurrent use. Would cause receptor desensitization
• Glucocorticoids: high-dose can suppress HPG axis

Gonadorelin sits in the HPG axis modulation category alongside several alternative approaches:

• Kisspeptin-10 and Kisspeptin-54: hypothalamic neuropeptides that act upstream of GnRH, stimulating endogenous GnRH release. Mechanistically a level higher than gonadorelin. Limited 503A availability. Investigational for HPG axis modulation.
• HCG (human chorionic gonadotropin): not strictly a peptide in the same category, but the principal alternative for TRT adjunct testicular preservation. Acts directly on testicular Leydig cells (LH mimetic). Longer half-life. More established clinical use. No FSH stimulation.
• Clomiphene and Enclomiphene: oral SERMs that block hypothalamic estrogen feedback, increasing endogenous LH and FSH. Different mechanism. Different practical profile (oral vs injection).
• GnRH agonists (Leuprolide, Goserelin): same receptor target but used for the opposite clinical purpose (chemical castration through receptor desensitization). Mechanistically informative as the mirror image of gonadorelin's intended use.
• PT-141: melanocortin receptor agonist for sexual dysfunction. Different mechanism, different indication, but in the sexual-health peptide category.

Common stacks circulating in TRT and post-cycle contexts:

• TRT + Gonadorelin: the dominant off-label stack. Goal: preserve testicular function and fertility while on exogenous testosterone. Typical: testosterone cypionate 100-200 mg/week + gonadorelin 100-200 mcg daily SC, or 200-400 mcg 2-3x/week.
• TRT + HCG: alternative testicular preservation stack. Goal: same as gonadorelin stack. Choice between HCG and gonadorelin often comes down to supply availability and provider preference.
• TRT + Gonadorelin + HCG: occasional combined approach for maximum testicular function preservation. Some clinicians prefer this for fertility-focused patients.
• PCT (post-cycle therapy) after AAS: gonadorelin + clomiphene + sometimes HCG to recover HPG axis function after exogenous androgen suppression.
• Diagnostic HPG axis testing: occasional clinical use mimicking original Factrel indication.

Combinations to avoid or use with caution:

• GnRH agonists (leuprolide, goserelin): avoid concurrent use. Opposite intended effect
• Hormone-sensitive cancers (prostate, breast): contraindicated
• Active pituitary tumors: caution
• Pregnancy and breastfeeding: contraindicated
• Athletes subject to WADA testing: doping violation

The most actionable framing of Gonadorelin in 2026: this is a well-characterized synthetic GnRH with a clean historical safety record in its FDA-approved indications. The current dominant use (off-label TRT adjunct for testicular preservation) is widely practiced but lacks controlled clinical trial validation. The pharmacokinetic mismatch between gonadorelin's 2-4 minute half-life and typical multi-day dosing schedules raises questions about whether routine off-label protocols achieve physiologically meaningful pituitary stimulation. Patients pursuing TRT with fertility preservation have multiple options (gonadorelin, HCG, enclomiphene, combinations), and the choice depends on individual goals, provider experience, and pharmaceutical access. The 503A compounding regulatory status is contested and could change with FDA enforcement actions. For patients prioritizing fertility preservation on TRT, working with an experienced reproductive endocrinologist is more meaningful than the specific choice of testicular preservation agent.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.